Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christiana Davis

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Respiratory Cell and Molecular Biology|July 23, 2003
Surfactant protein-D, a mediator of innate lung immunity, alters the products of nitric oxide metabolismElena N Atochina, Michael F Beers, Samuel Hawgood, et al.
JTO Clinical and Research Reports|May 27, 2024
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLCDavid J Cantor, Christiana Davis, Christine Ciunci, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanomaJeffrey C Thompson, Christiana Davis, Charuhas Deshpande, et al.
Cancers|August 29, 2024
Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line PatientsJeffrey C Thompson, Caitlin Tilsed, Christiana Davis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2019
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracyJeffrey C Thompson, Wei-Ting Hwang, Christiana Davis, et al.
JAMA Oncology|July 12, 2019
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 TrialJoshua M Bauml, Rosemarie Mick, Christine Ciunci, et al.
JTCVS Open|April 10, 2026
Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non-small cell lung cancer: 5-Year outcomesAidan Aicher, David Rekhtman, Ella Eisinger, et al.
JCO Oncology Practice|October 25, 2021
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO RegistryKathryn F Mileham, Suanna S Bruinooge, Charu Aggarwal, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Respiratory Cell and Molecular Biology|July 23, 2003
Surfactant protein-D, a mediator of innate lung immunity, alters the products of nitric oxide metabolismElena N Atochina, Michael F Beers, Samuel Hawgood, et al.
JTO Clinical and Research Reports|May 27, 2024
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLCDavid J Cantor, Christiana Davis, Christine Ciunci, et al.
Journal for Immunotherapy of Cancer|October 8, 2020
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanomaJeffrey C Thompson, Christiana Davis, Charuhas Deshpande, et al.
Cancers|August 29, 2024
Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line PatientsJeffrey C Thompson, Caitlin Tilsed, Christiana Davis, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2019
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracyJeffrey C Thompson, Wei-Ting Hwang, Christiana Davis, et al.
JAMA Oncology|July 12, 2019
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 TrialJoshua M Bauml, Rosemarie Mick, Christine Ciunci, et al.
JTCVS Open|April 10, 2026
Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non-small cell lung cancer: 5-Year outcomesAidan Aicher, David Rekhtman, Ella Eisinger, et al.
JCO Oncology Practice|October 25, 2021
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO RegistryKathryn F Mileham, Suanna S Bruinooge, Charu Aggarwal, et al.
Pageof 1